Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma

Roswell Park Cancer Institute1 site in 1 country15 target enrollmentJuly 11, 2013

ConditionsRecurrent Renal Cell Cancer Stage IV Renal Cell Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Recurrent Renal Cell Cancer
Sponsor: Roswell Park Cancer Institute
Enrollment: 15
Locations: 1
Primary Endpoint: Feasibility of conducting a partial nephrectomy in patients with no prior stereotactic radiation for kidney cancer
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed Description

PRIMARY OBJECTIVES: I. Assess the impact of stereotactic body radiation therapy (SBRT) on the immune system in patients with metastatic renal cell carcinoma (RCC). SECONDARY OBJECTIVES: I. Assess changes in immune parameters prior to radiation, post radiation and post nephrectomy. TERTIARY OBJECTIVES: I. Assess surgical parameters for partial or radical nephrectomy post SBRT. OUTLINE: Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29. After completion of study treatment, patients are followed up at 30 days.

Registry

clinicaltrials.gov

Start Date

July 11, 2013

End Date

December 30, 2016

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Roswell Park Cancer Institute

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have metastatic RCC with primary tumor in place
•Must be surgical candidates as deemed fit by surgeon
•Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
•Patients of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
•Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria

•Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
•Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
•Radiation to primary tumor prior to enrollment in this study
•Pregnant or nursing female patients
•Unwilling or unable to follow protocol requirements
•Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive treatment
•Received an investigational agent within 30 days prior to enrollment